STOCKS TELEGRAPH

Tag: BCTX stock

BriaCell Therapeutics (BCTX) Sees Stock Boost On Promising Trial News

As of the last check today, BriaCell Therapeutics Corp. (NASDAQ: BCTX) shares were trading 23.20% up at $4.62 on the stock charts. The surge followed the company’s positive clinical trial results.

Excellent Results for HR+ Metastatic Breast Cancer

Following the publication of revised results from its Phase 2 study assessing the Bria-IMT regimen in conjunction with checkpoint inhibitors (CPI), which demonstrated improved survival outcomes in patients with metastatic breast cancer (MBC), BCTX stock experienced a strong increase.

Patients with late-stage MBC, especially those with hormone receptor-positive (HR+) illness, were the focus of the Phase 2 investigation. Twenty-five of the 37 patients who received treatment with BriaCell’s current pivotal Phase 3 formulation of Bria-IMT were found to be HR+.

The median survival for these patients was 17.3 months, which was higher than the 14.4-month survival with TRODELVY, an antibody-drug conjugate (ADC) that is thought to be the standard of therapy for this population.

Boosting Triple-Negative Breast Cancer Outcomes

In the triple-negative breast cancer (TNBC) group, a particularly difficult subtype devoid of HER2, progesterone, and estrogen receptors, the Bria-IMT + CPI regimen also produced noteworthy outcomes. While survival in this group was comparable to that achieved with TRODELVY, it exceeded traditional chemotherapy outcomes by 70%, underscoring the regimen’s therapeutic potential.

Well-Tolerated Therapy Shows Broad Potential

There have been no documented treatment-related discontinuations as of yet, indicating that the Bria-IMT regimen has shown excellent tolerability. These results support BriaCell’s theory that Bria-IMT and CPI together might provide HR+ and TNBC patients—groups who presently have few therapy options and dismal prognoses—with a useful treatment option.

Of the 54 patients with MBC who were significantly pre-treated in BriaCell’s Phase 2 study, 37 were given the formulation that is currently being employed in its key Phase 3 trial. BCTX will continue evaluating overall survival as the primary endpoint in this ongoing study, aiming to confirm the promising Phase 2 results and address the unmet medical needs in this difficult-to-treat population.

April 16, 2025
BriaCell Therapeutics Corp. (BCTX) Stock Undergoes Volatility Ahead of Expanded Cancer Platform Technology Announcement

BriaCell Therapeutics Corp. (BCTX) stock prices were up by a hefty 8.96% as of the market closing on June 16^th, 2021, bringing the price per share up to USD$6.57 at the end of the trading day. After-hours trading, however, saw the stock drop by 9.28%, bringing it down to USD$5.96.

Oncology Therapeutics

The company announced on June 16^th, 2021 the advancement of its targeted oncology therapeutics into various respective immunotherapy cell lines. Among these are Bria-Pros for prostrate cancer, Bria-Mel for melanoma, and Bria-Lung for lung cancer. The treatment was most effective in breast cancer when patient HLA-type matched with the targeted immunotherapy, owing to the potential afforded to Briacell to identify patients most likely to respond to the treatment.

HLA-Type Testing

This innovative approach makes use of human leukocyte antigen (HLA-type) testing, which is both simple to use and widely available, making it a highly accessible resource. With the use of its proprietary cell engineering technology, the company is now developing off-the-shelf personalized immunotherapy for various cancer indications, which utilizes the HLA-matching platform technology.

Bria-Pros

Bria-Pros is an off-the-shelf personalized treatment for prostate cancer, which is the second most common cancer among men in the US and one of the leading causes of cancer deaths in men. Existing treatments for metastatic prostate cancer include immunotherapy, hormone therapy, chemotherapy, and targeted treatments. However, there is much ground left to be broken in prostate cancer therapies, seeing how none of the existing ones are curative.

Bria-Mel

Bria-Mel is personalized immunotherapy for melanoma, with off-the-shelf availability. With more than 80,000 melanoma diagnoses being administered in the US alone, the disease claims the lives of more than 8000 patients every year. Immunotherapy, targeted therapy, and chemotherapy are options in the treatment for advanced melanoma, with there being a large unaddressed need for new safe and effective therapies for melanoma.

Bria-Lung

Bria-Lung is designed as personalized immunotherapy for lung cancer, being available off-the-shelf. Being the third most common type of cancer in the world, more than 130,000 Americans succumb to it every year. The most common form of lung cancer is called non-small cell lung cancer (NSCLC) and its spread (metastasis). With treatments including targeted therapies, immunotherapy, and chemotherapy, no treatment is likely to cure the cancers, indicating a large unmet need.

Future Outlook for BCTX

Armed with the development of accessible treatments that the company hopes will address large sections of unmet need, BCTX is poised to push for the proliferation of the treatments to expand and consolidate their market footprint. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

June 17, 2021
BriaCell Therapeutics Corp. (BCTX) stock increased over 10% in Pre-Market: Let’s find out why

Share of BriaCell Therapeutics Corp. (BCTX) surpassed 10% in the pre-market trading session today. BCTX stock saw a push of 13.82% to reach $5.93 a share at the time of this writing. It seems that BCTX stock continued the rising momentum as it went up by 18.95% at the previous closing. But what made the stock high in the stock market? Let’s try to find it.

What’s happening?

There is no particular news by the BriaCell stock today to justify the bull. No signs of analyst upgrades or upswing BCTX per share targeted price to explain the rally. However, BrialCell announced on March 30 about its selection to present the analysis result of its research related to breast cancer at the American Association for Cancer Research (AACR) Annual Meeting 2021. The dates announced for the meeting were April 10 to 15 and May 17 – 21.

The first week of the meeting is ongoing and there is a strong possibility that investors are responding to the results announced by the company in the meeting. The analysis result to be announced in the meeting would be related to the clinical analysis and pathological data of BriaCell’s lead product, Bria-IMT for treatment of advanced breast cancer as well as Phase I/IIa clinical study of Bria-IMTin combination with immune checkpoint inhibitors which include pembrolizumab, a Merck’s product, and INCMGA00012, a product of Incyte Corporation.

BCTX stock previous news:

On February 26, 2021, BCTX stock closed the underwritten public offering of its common units. 4,852,353 common units were offered in that offering with US$4.25 per unit purchase price. Each unit consisted of one share of common stock of BCTX along with one warrant to the purchase of one share of BCTX’s common stock. 1,030,000 pre-funded units were offered at the public price of US$4.24 each and consisted of a pre-funded purchase warrant of common stock and one Warrant. The US$25 million gross proceeds resulted from this offering without deducting the underwriting discounts and other related expenses.

Conclusion:

BCTX stock price is continuously rising despite no recent news by BriaCell Therapeutics. It would be interesting to see how long this trend would continue in the future. The final results of research related to breast cancer would greatly influence the future of the BriaCell stock.

April 12, 2021